Skip to content

Study · Randomized controlled trial · n = 88 · 2015

6 results

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B and 7 more

Show all authors

Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K

Drug design, development and therapy3 Sept 2015Cited by 143 (Europe PMC)

PMID26366058 (opens in a new tab)PMCIDPMC4562767 (opens in a new tab)DOI10.2147/dddt.s84177 (opens in a new tab)PepBankPUB-26366058
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In refractory carcinoid symptoms, control occurred in 20.9% with pasireotide LAR versus 26.7% with octreotide LAR (P=0.53).

    In plain wordsIn refractory carcinoid symptoms, control was numerically lower with pasireotide LAR than octreotide LAR, without a significant difference.

    Peptide
    Pasireotide
    Outcome
    DecreaseCarcinoid symptom control
    Study

    n = 88

    Comparator
    Octreotide LAR 40 mg every 28 days
    Analysis
    Primary
    Outcome group
    Disease Signs And Symptoms · Cancer
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Symptom control
    20.9%
    pasireotide LAR; n = 43
    Symptom control
    26.7%
    octreotide LAR; n = 45
    Odds ratio
    0.73
    pasireotide LAR vs octreotide LAR
    95% CI of odds ratio
    0.27 to 1.97
    pasireotide LAR vs octreotide LAR
    P value
    0.53
    pasireotide LAR vs octreotide LAR

    Source sentences

    Summary
    because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In refractory carcinoid tumors, median progression-free survival was 11.8 months with pasireotide versus 6.8 months with octreotide (HR 0.46, P=0.045).

    In plain wordsIn refractory carcinoid tumors, progression-free survival was longer with pasireotide than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseProgression-free survival
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 40 mg every 28 days
    Analysis
    Exploratory
    Outcome group
    Tumor growth · Cancer
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Median progression-free survival
    11.8 months
    pasireotide LAR
    95% CI lower limit (upper limit not reached)
    11 months
    pasireotide LAR median PFS
    Median progression-free survival
    6.8 months
    octreotide LAR
    95% CI lower limit (upper limit not reached)
    5.6 months
    octreotide LAR median PFS
    Hazard ratio
    0.46
    pasireotide LAR vs octreotide LAR
    95% CI of hazard ratio
    0.2 to 0.98
    pasireotide LAR vs octreotide LAR
    P value
    0.045
    pasireotide LAR vs octreotide LAR

    Source sentences

    Summary
    Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In refractory carcinoid tumors, month 6 tumor control was 62.7% with pasireotide versus 46.2% with octreotide (P=0.09).

    In plain wordsIn refractory carcinoid tumors, tumor control was numerically higher with pasireotide than octreotide at month 6, without a significant difference.

    Peptide
    Pasireotide
    Outcome
    IncreaseTumor control at month 6
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 40 mg every 28 days
    Outcome group
    Tumor growth · Cancer
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Tumor control rate at month 6
    62.7%
    pasireotide LAR
    Tumor control rate at month 6
    46.2%
    octreotide LAR
    Odds ratio
    1.96
    pasireotide LAR vs octreotide LAR
    95% CI of odds ratio
    0.89 to 4.32
    pasireotide LAR vs octreotide LAR
    P value
    0.09
    pasireotide LAR vs octreotide LAR

    Source sentences

    Summary
    Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.
  4. 04HumanRandomized controlled trialSafety outcome

    In refractory carcinoid tumors, drug-related hyperglycemia occurred in 28.3% with pasireotide versus 5.3% with octreotide.

    In plain wordsIn refractory carcinoid tumors, drug-related high blood glucose was more frequent with pasireotide than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseHyperglycemia
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 40 mg every 28 days
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Drug-related hyperglycemia
    28.3%
    pasireotide LAR
    Drug-related hyperglycemia
    5.3%
    octreotide LAR

    Source sentences

    Summary
    The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.
  5. 05HumanRandomized controlled trialSafety outcome

    In refractory carcinoid tumors, drug-related fatigue occurred in 11.3% with pasireotide versus 3.5% with octreotide.

    In plain wordsIn refractory carcinoid tumors, drug-related fatigue was more frequent with pasireotide than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseFatigue
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 40 mg every 28 days
    Outcome group
    Adverse events · Whole body
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Drug-related fatigue
    11.3%
    pasireotide LAR
    Drug-related fatigue
    3.5%
    octreotide LAR

    Source sentences

    Summary
    The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.
  6. 06HumanRandomized controlled trialSafety outcome

    In refractory carcinoid tumors, drug-related nausea occurred in 9.4% with pasireotide versus 0% with octreotide.

    In plain wordsIn refractory carcinoid tumors, drug-related nausea was more frequent with pasireotide than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseNausea
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 40 mg every 28 days
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    60 mg every 28 daysAs given in this study (human).

    Measurements

    Drug-related nausea
    9.4%
    pasireotide LAR
    Drug-related nausea
    0%
    octreotide LAR

    Source sentences

    Summary
    The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%).
    2 context sentences
    Summary · context
    In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues.
    Summary · context
    Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.